Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XE3D | ISIN: IE00BJMZDW83 | Ticker-Symbol: DHG
Frankfurt
07.11.24
08:10 Uhr
4,490 Euro
+0,095
+2,16 %
Branche
Hotels/Tourismus
Aktienmarkt
ISEQ-20
1-Jahres-Chart
DALATA HOTEL GROUP PLC Chart 1 Jahr
5-Tage-Chart
DALATA HOTEL GROUP PLC 5-Tage-Chart
RealtimeGeldBriefZeit
4,5054,53018:31
Dow Jones News
160 Leser
Artikel bewerten:
(1)

Dalata Hotel Group PLC: Dalata Hotel Group announces the purchase of Radisson Hotel Dublin Airport for EUR83 million

DJ Dalata Hotel Group PLC: Dalata Hotel Group announces the purchase of Radisson Hotel Dublin Airport for EUR83 million

Dalata Hotel Group PLC (DAL,DHG) 
Dalata Hotel Group PLC: Dalata Hotel Group announces the purchase of Radisson Hotel Dublin Airport for EUR83 million 
06-Nov-2024 / 07:00 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
 
Dalata Hotel Group announces the purchase of Radisson Hotel Dublin Airport for EUR83 million 
Acquisition of strong revenue generating and in-demand hotel 
Existing four-star hotel to become a Clayton Hotel 
ISE: DHG         LSE: DAL 
Dublin and London | 6 November 2024: Dalata Hotel Group plc ('Dalata' or the 'Group'), the largest hotel operator in 
Ireland, with a growing presence in the United Kingdom and Continental Europe, announces that it has exchanged 
contracts for the purchase of the entire issued share capital of CG Hotels Dublin Airport Limited, which holds the long 
leasehold interest in The Radisson Hotel, Dublin Airport (the 'Hotel' or the 'Property'), for a consideration of EUR83 
million (the 'Transaction'), subject to contractual conditions and regulatory approval. The vendor is a related party 
of Emerald Investment. Windward Management has been the hotel operating partner. The total consideration will be 
financed from Dalata's existing cash and banking facilities. 
The existing Property, on 4.4 acres, located at Dublin Airport, is a four-star hotel with full four-star facilities 
consisting of 229 bedrooms, extensive meeting and event facilities, bar, restaurant, and substantial on-site parking. 
The current Hotel had an EBITDA pre franchise fees and management fees, of approximately EUR6.5 million in 2023 with 
consolidated gross assets of EUR83 million at December 2023, and requires limited initial investment as it underwent a 
significant refurbishment programme in 2019. The Hotel also enjoys the benefit of two significant planning approvals, 
offering development opportunities into the future. Upon completion of the Transaction, the Hotel will be rebranded as 
a Clayton hotel. The remaining tenure of the leasehold is 107 years, and the Transaction is scheduled to close in H1 
2025, subject to CCPC (Competition and Consumer Protection Commission) approval. 
Dublin remains a strategic growth market for Dalata and this Transaction, with the Maldron Hotel Dublin Airport 
operating licence due to expire in January 2026, represents a very attractive opportunity for the Group to secure a 
well invested four-star hotel, in close proximity to Terminal 2 in Dublin Airport. 
Shane Casserly, Deputy CEO of Dalata Hotel Group commented: "The acquisition of this Hotel is a compelling opportunity 
to secure a strong revenue generating hotel, in an excellent location. This Hotel is well positioned to provide 
hospitality services to Dublin Airport passengers and the greater north Dublin community, supporting both the local and 
national economies. The Hotel aligns with our investment criteria and offers us the very attractive opportunity to 
invest and further develop the Hotel offering on the overall site, delivering greater investment returns into the 
future. 
Our advisors are ready to engage with the CCPC immediately and subject to their approval, we look forward to welcoming 
the Hotel and our new colleagues into Dalata in the first half of 2025." 
Dermot Crowley, CEO of Dalata Hotel Group commented: "This acquisition is an exceptional opportunity in a vibrant hotel 
market. We will continue to balance disciplined growth, capital efficiency and financial strength with returns to 
shareholders". 
ENDS 
About Dalata 
Dalata Hotel Group plc is a leading hotel operator backed by EUR1.7bn in hotel assets primarily in Ireland and the UK. 
Established in 2007, Dalata has become Ireland's largest hotel operator with an ambitious growth strategy to expand its 
portfolio further in excellent locations in select, large cities in the UK and Continental Europe. The Group's 
portfolio comprises a mix of owned and leased hotels with 57 primarily four-star hotels operating through its two main 
brands, Clayton and Maldron Hotels, with 12,258 rooms and a pipeline of over 700 rooms. For the six-month period ended 
30 June 2024, Dalata reported revenue of EUR302 million, basic earnings per share of 16.0 cent and Free Cashflow per 
Share of 21.5 cent. Dalata is listed on the Main Market of Euronext Dublin (DHG) and the London Stock Exchange (DAL). 
For further information visit: www.dalatahotelgroup.com 
Contacts 
Dalata Hotel Group plc           Tel +353 1 206 9400 
Dermot Crowley, CEO            investorrelations@dalatahotelgroup.com 
Shane Casserly, Deputy CEO 
Carol Phelan, CFO 
 Niamh Carr, Head of Investor Relations & Strategic Forecasting 
 
Joint Company Brokers 
Davy: Anthony Farrell           Tel +353 1 679 6363 
Berenberg: Ben Wright           Tel +44 20 3753 3069 
 
Investor Relations and PR | FTI Consulting Tel +353 87 737 9089 
                      Tel +353 85 277 9905 
Sam Moore/ Rugile Nenortaite 
                      dalata@fticonsulting.com 

----------------------------------------------------------------------------------------------------------------------- Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

ISIN:      IE00BJMZDW83, IE00BJMZDW83 
Category Code: MSCM 
TIDM:      DAL,DHG 
LEI Code:    635400L2CWET7ONOBJ04 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:  357268 
EQS News ID:  2023193 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2023193&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

November 06, 2024 02:00 ET (07:00 GMT)

© 2024 Dow Jones News
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.